PGI Is Contemplating To Start In-House Testing Of Medicines

CHANDIGARH : After the recent cases of drug contamination and adverse events at PGI, the institute is contemplating to start in-house testing of medicines, a facility lacking in any public hospital in the country.

There are regional and central drugs laboratories and some private centres which are approved by the DCGI to test and analyse suspected medicine samples. No hospital has the large scale facility or infrastructure for testing medicine safety and efficacy.

“We are actively working on it. It should be operational sooner than later. It will be a double check. We will not have to depend on outside resources,” said Prof Vivek Lal, director, PGI.

After five deaths of patients who were to be operated upon and were administered sedative drug Propofol, the PGI had sent the samples of the medicine to the drug control authorities in the city. It took almost a month for the test analysis report. With the in-house testing, the hospital will be able to conclude with evidence if the adverse event was due to the medicines or other complications.

“The sample was also tested by the pharmacology department in the PGI and in Panjab University. But in the absence of the requisite infrastructure/reagents, the test was not as validated as from the approved government testing laboratories,” said a faculty member at PGI.

The laboratory will follow pharmacopoeia monographs — documents which are taken as reference for testing of drugs — and had to be good manufacturing practice compliant. “When the facility is ready, suspected drugs will be tested here prior to giving it to the patients who are admitted for surgery or for treatment. However, for any legal action, the samples will also be sent to the approved government laboratories,” said a senior faculty member.

  • Related Posts

    FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

    The Maharashtra Food and Drug Administration (FDA) seized 3,098.46 tonnes of food stock worth Rs 63.45 crore and suspended 954 food licences during a statewide enforcement drive in the past…

    Stents to syringes: Serious harm reports surge, but makers remain unnamed

    6-year data disclosed first time by Indian Pharmacopoeia Commission on CIC order The Indian Pharmacopoeia Commission (IPC) has, for the first time, disclosed the number of Serious Adverse Events (SAEs)…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

    FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

    Stents to syringes: Serious harm reports surge, but makers remain unnamed

    Stents to syringes: Serious harm reports surge, but makers remain unnamed

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Medicines that cure Us are making Our Environment Sick

    Medicines that cure Us are making Our Environment Sick